Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY CEFP Working Group to Go Full Throttle on Policy Guidelines Debate in March
February 22, 2017
-
REGULATORY New Formats for Package Inserts to Be Announced in April, Enforced from FY2019 with Transition Period: MHLW
February 21, 2017
-
ACADEMIA AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
-
REGULATORY MHLW Advisory Panel to Review Shionogi’s ADHD Drug on March 2
February 17, 2017
-
TRENDS Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
-
REGULATORY With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
-
BUSINESS Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
-
BUSINESS Bristol-Myers Looks to Crack into Genotype 1 Hep C Market as Ximency Clears Resistance Mutation Hurdle
February 15, 2017
-
REGULATORY MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
-
REGULATORY Japan’s First Guidance for Development of Cancer Immunotherapies Will Promote Development
February 13, 2017
-
BUSINESS Bayer Yakuhin Ramping Up Digital Transformation: New President
February 10, 2017
-
BUSINESS Harvoni No. 1 Drug in Japan in 2016 with Sales of 296 Billion Yen, More than Any Other Drug Over Past 10 Years: IMS Japan
February 10, 2017
-
REGULATORY Bill Payers, Doctors in Skirmish over Drug Price Survey for Gap-Year Revisions: Chuikyo
February 9, 2017
-
REGULATORY Chuikyo OKs Optimal Use Guidelines for Opdivo and Keytruda, Due Out Feb. 14
February 9, 2017
-
REGULATORY Keytruda Gets Same Daily Price as Opdivo; Chuikyo OKs Batch of Drugs for Feb. 15 Listing
February 8, 2017
-
INTERVIEW CEO Weber Says Takeda’s Ongoing Transformation “Irreversible”: Full Interview
February 8, 2017
-
TRENDS Montelukast AG Achieves Rapid Market Penetration, Enjoys Stronger Start than Candesartan AG
February 7, 2017
-
BUSINESS Takeda Wants to Be Global GI Leader in 2025, Not in Acquisition Frenzy Mode: CEO
February 3, 2017
-
ORGANIZATION US Exclusion from Foreign Price Adjustment Should Be Carefully Considered: PhRMA Japan Chief
February 2, 2017
-
REGULATORY MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…